PL3752173T3 - Połączenie różeńca i traganka w leczeniu chorób neurodegeneracyjnych - Google Patents

Połączenie różeńca i traganka w leczeniu chorób neurodegeneracyjnych

Info

Publication number
PL3752173T3
PL3752173T3 PL19710055.5T PL19710055T PL3752173T3 PL 3752173 T3 PL3752173 T3 PL 3752173T3 PL 19710055 T PL19710055 T PL 19710055T PL 3752173 T3 PL3752173 T3 PL 3752173T3
Authority
PL
Poland
Prior art keywords
rhodiola
astragalus
treatment
combination
neurodegenerative diseases
Prior art date
Application number
PL19710055.5T
Other languages
English (en)
Inventor
Gérald GOUDET
Original Assignee
Human By Nature
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1851298A external-priority patent/FR3077730B1/fr
Application filed by Human By Nature filed Critical Human By Nature
Publication of PL3752173T3 publication Critical patent/PL3752173T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL19710055.5T 2018-02-15 2019-02-15 Połączenie różeńca i traganka w leczeniu chorób neurodegeneracyjnych PL3752173T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1851298A FR3077730B1 (fr) 2018-02-15 2018-02-15 Combinaison de rhodiole et d'astragale pour le traitement de maladies neurodegeneratives
FR1851319 2018-02-16
PCT/FR2019/050342 WO2019158870A1 (fr) 2018-02-15 2019-02-15 Combinaison de rhodiole et d'astragale pour le traitement de maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
PL3752173T3 true PL3752173T3 (pl) 2025-08-04

Family

ID=65724446

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710055.5T PL3752173T3 (pl) 2018-02-15 2019-02-15 Połączenie różeńca i traganka w leczeniu chorób neurodegeneracyjnych

Country Status (9)

Country Link
US (1) US11771730B2 (pl)
EP (1) EP3752173B1 (pl)
JP (1) JP7438957B2 (pl)
DK (1) DK3752173T3 (pl)
ES (1) ES2971544T3 (pl)
FI (1) FI3752173T3 (pl)
PL (1) PL3752173T3 (pl)
PT (1) PT3752173T (pl)
WO (1) WO2019158870A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113101007B (zh) * 2021-03-23 2022-05-27 武汉理工大学 一种载药纳米纤维神经导管的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030007104A (ko) * 2001-07-10 2003-01-23 주식회사 유젠바이오 베르베린, 그의 유도체 및 약학적으로 허용되는 그의 염을함유하는 신경세포 보호 및 재생용 조성물
CN100525809C (zh) * 2005-12-05 2009-08-12 山东轩竹医药科技有限公司 由黄芪、红景天和菝葜制成的药物组合物及其制备方法
US7390512B2 (en) 2006-09-29 2008-06-24 Jose Angel Olalde Rangel Multiple sclerosis synergistic phyto-nutraceutical composition
US7553503B2 (en) * 2006-11-16 2009-06-30 Jose Angel Olalde Rangel Phyto-nutraceutical synergistic composition for Parkinson's Disease
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
CN102940787A (zh) 2012-11-09 2013-02-27 西安福安创意咨询有限责任公司 治疗高血压的中药

Also Published As

Publication number Publication date
US20210052683A1 (en) 2021-02-25
JP7438957B2 (ja) 2024-02-27
ES2971544T3 (es) 2024-06-05
RU2020130061A (ru) 2022-03-15
US11771730B2 (en) 2023-10-03
JP2021513991A (ja) 2021-06-03
EP3752173B1 (fr) 2023-12-20
FI3752173T3 (fi) 2024-03-01
PT3752173T (pt) 2024-02-09
CA3090958A1 (fr) 2019-08-22
RU2020130061A3 (pl) 2022-03-15
DK3752173T3 (da) 2024-01-29
EP3752173A1 (fr) 2020-12-23
WO2019158870A1 (fr) 2019-08-22

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL276398A (en) Combined treatment for mastocytosis
SG11202104923YA (en) Pharmaceutical combination for treatment of cancer
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
PL3577135T3 (pl) Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL280337A (en) LAG-3 combination therapy for cancer treatment
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
ZA201805407B (en) Composition for the prevention or treatment of neurodegenerative diseases.
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL286767A (en) Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL283948A (en) Methods for treating depression
SG11202005874TA (en) Pharmaceutical composition for the treatment of cancer
HUE069820T2 (hu) Nalfurafin alkalmazása demielinizációs betegségek kezelésére
IL284162A (en) Integrated healing for cancer treatment
GB201714307D0 (en) Treatment of neurodegenerative diseases
IL281782A (en) Drug combination for cancer treatment
PT3752173T (pt) Combinação de rhodiola e de astragalus para o tratamento de doenças neurodegenerativas.
GB201714303D0 (en) Treatment of neurodegenerative diseases
PL3586832T3 (pl) Kompozycja farmaceutyczna do leczenia zaparcia
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
HK40058924A (en) Pharmaceutical combination for the treatment of cancer